Akebia Therapeutics Inc
NASDAQ:AKBA

Watchlist Manager
Akebia Therapeutics Inc Logo
Akebia Therapeutics Inc
NASDAQ:AKBA
Watchlist
Price: 1.59 USD 0.63% Market Closed
Market Cap: 421.9m USD

Akebia Therapeutics Inc
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Akebia Therapeutics Inc
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Akebia Therapeutics Inc
NASDAQ:AKBA
Pre-Tax Income
-$15.3m
CAGR 3-Years
54%
CAGR 5-Years
48%
CAGR 10-Years
11%
Abbvie Inc
NYSE:ABBV
Pre-Tax Income
$1.7B
CAGR 3-Years
-52%
CAGR 5-Years
-27%
CAGR 10-Years
-8%
Gilead Sciences Inc
NASDAQ:GILD
Pre-Tax Income
$9.9B
CAGR 3-Years
30%
CAGR 5-Years
41%
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Pre-Tax Income
$8.2B
CAGR 3-Years
2%
CAGR 5-Years
0%
CAGR 10-Years
1%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Pre-Tax Income
$4.4B
CAGR 3-Years
3%
CAGR 5-Years
9%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Pre-Tax Income
$5.1B
CAGR 3-Years
-5%
CAGR 5-Years
8%
CAGR 10-Years
16%
No Stocks Found

Akebia Therapeutics Inc
Glance View

Market Cap
421.7m USD
Industry
Biotechnology

Akebia Therapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics for patients with kidney diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 426 full-time employees. The company went IPO on 2014-03-20. The firm is focused on producing medicines for people living with kidney disease. Its lead product candidate, vadadustat, is an oral therapy in development for the treatment of anemia due to chronic kidney disease (CKD). Vadadustat is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), designed to mimic the physiologic effect of altitude on oxygen availability. In addition, it has a commercial product, Auryxia (ferric citrate), which is marketed for two indications in the United States: the control of serum phosphorus levels in adult patients with dialysis-dependent (DD)-CKD or the hyperphosphatemia indication, and the treatment of iron deficiency anemia (IDA), in adult patients with non-dialysis dependent (NDD)-CKD or the IDA indication. Its ferric citrate is also approved and marketed in Japan as an oral treatment for the improvement of hyperphosphatemia in patients with CKD.

AKBA Intrinsic Value
3.41 USD
Undervaluation 53%
Intrinsic Value
Price

See Also

What is Akebia Therapeutics Inc's Pre-Tax Income?
Pre-Tax Income
-15.3m USD

Based on the financial report for Sep 30, 2025, Akebia Therapeutics Inc's Pre-Tax Income amounts to -15.3m USD.

What is Akebia Therapeutics Inc's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 10Y
11%

Over the last year, the Pre-Tax Income growth was 67%. The average annual Pre-Tax Income growth rates for Akebia Therapeutics Inc have been 54% over the past three years , 48% over the past five years , and 11% over the past ten years .

Back to Top